These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 1671032)

  • 41. [A rare and not very studied disorder: childhood-onset schizophrenia. A case report].
    Bailly D; de Chouly de Lenclave MB
    Encephale; 2004; 30(6):540-7. PubMed ID: 15738856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conceptualizing schizophrenia through attenuated symptoms in the population.
    Carpenter WT
    Am J Psychiatry; 2010 Sep; 167(9):1013-6. PubMed ID: 20826849
    [No Abstract]   [Full Text] [Related]  

  • 43. Impairment in flexible emotion-based learning in hallucination- and delusion-prone individuals.
    Cella M; Dymond S; Cooper A
    Psychiatry Res; 2009 Nov; 170(1):70-4. PubMed ID: 19819023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duration of untreated psychosis and time to treatment response for delusions and hallucinations.
    Gunduz-Bruce H; McMeniman M; Robinson DG; Woerner MG; Kane JM; Schooler NR; Lieberman JA
    Am J Psychiatry; 2005 Oct; 162(10):1966-9. PubMed ID: 16199847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms.
    Bliksted V; Videbech P; Fagerlund B; Frith C
    Neuropsychology; 2017 Feb; 31(2):209-219. PubMed ID: 27808537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia.
    Mancevski B; Keilp J; Kurzon M; Berman RM; Ortakov V; Harkavy-Friedman J; Rosoklija G; Dwork AJ
    Psychopathology; 2007; 40(2):83-92. PubMed ID: 17215594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive correlates of schizophrenia signs and symptoms: III. Hallucinations and delusions.
    Berenbaum H; Kerns JG; Vernon LL; Gomez JJ
    Psychiatry Res; 2008 May; 159(1-2):163-6. PubMed ID: 18423619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationships between medication treatments and neuropsychological test performance in schizophrenia.
    Sweeney JA; Keilp JG; Haas GL; Hill J; Weiden PJ
    Psychiatry Res; 1991 Jun; 37(3):297-308. PubMed ID: 1679950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Developmental and neurologic correlates of treatment response in schizophrenia.
    Whelton CL; Cleghorn JM; Atley S; Durocher GJ; MacCrimmon D
    J Psychiatry Neurosci; 1992 Mar; 17(1):15-22. PubMed ID: 1349824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delusions and hallucinations in patients with borderline personality disorder.
    Suzuki H; Tsukamoto C; Nakano Y; Aoki S; Kuroda S
    Psychiatry Clin Neurosci; 1998 Dec; 52(6):605-10. PubMed ID: 9895209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toward a new approach to schizophrenic psychosis.
    Morin DC
    Psychol Rep; 1995 Feb; 76(1):123-9. PubMed ID: 7770554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Probabilistic reasoning in schizophrenia: a comparison of the performance of deluded and nondeluded schizophrenic patients and exploration of possible cognitive underpinnings.
    Menon M; Pomarol-Clotet E; McKenna PJ; McCarthy RA
    Cogn Neuropsychiatry; 2006 Nov; 11(6):521-36. PubMed ID: 17354086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey.
    Lecrubier Y; Perry R; Milligan G; Leeuwenkamp O; Morlock R
    Eur Psychiatry; 2007 Sep; 22(6):371-9. PubMed ID: 17521890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perseveration and over-switching in schizophrenia.
    Yogev H; Hadar U; Gutman Y; Sirota P
    Schizophr Res; 2003 Jun; 61(2-3):315-21. PubMed ID: 12729883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic drug effects on cognitive function in schizophrenia.
    Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM
    Schizophr Res; 1990; 3(3):211-9. PubMed ID: 1980613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.
    Ziedonis D; Richardson T; Lee E; Petrakis I; Kosten T
    Psychopharmacol Bull; 1992; 28(3):309-14. PubMed ID: 1480735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug abuse in schizophrenic patients: clinical correlates and reasons for use.
    Dixon L; Haas G; Weiden PJ; Sweeney J; Frances AJ
    Am J Psychiatry; 1991 Feb; 148(2):224-30. PubMed ID: 1987823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of cannabis abuse on schizophrenic psychopathology.
    Peralta V; Cuesta MJ
    Acta Psychiatr Scand; 1992 Feb; 85(2):127-30. PubMed ID: 1543037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medication compliance and substance abuse among schizophrenic patients.
    Pristach CA; Smith CM
    Hosp Community Psychiatry; 1990 Dec; 41(12):1345-8. PubMed ID: 1980483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Substance abuse in psychotic disorders: associations with affective syndromes. DSM-IV Field Trial Work Group.
    Strakowski SM; Tohen M; Flaum M; Amador X
    Schizophr Res; 1994 Dec; 14(1):73-81. PubMed ID: 7893624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.